Sinopharm Group Co. Ltd.
1099
Rang in Aktien
#2962
Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of... Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are organized across four main divisions. Its Pharmaceutical Distribution segment supplies pharmaceutical goods to a wide range of clients, including hospitals, fellow distributors, retail pharmacies, and clinics. This division additionally offers extensive distribution, logistics, and value-added support to both domestic and international manufacturers and suppliers in the pharmaceutical and healthcare sectors. The Medical Devices segment is solely focused on the distribution of various medical equipment. Through its Retail Pharmacy division, Sinopharm manages and franchises a vast chain of drug stores, with an impressive 10,259 locations as of December 31, 2021. The "Other Business" segment is involved in the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core areas, the company also engages in property rental and management. It further distributes specialized items such as medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products. Sinopharm provides a comprehensive array of services, including IT development, medicine and health consultations, investment services, import/export facilitation for goods and technology, various business and market information consulting, and the organization of conventions and exhibitions. Moreover, it oversees medical project investments, offers related consulting, and provides technological training. Notably, Sinopharm Group has established a strategic alliance with I-Mab to enhance its commercial capabilities and accelerate its market entry strategies. Founded in Shanghai, China, in 2003, Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Aktienkurs
$1.99
Marktkapitalisierung
$6.22B
Veränderung (1 Tag)
-0.95%
Veränderung (1 Jahr)
-17.30%
Land
CN
Handel Sinopharm Group Co. Ltd. (1099)
Kategorie
Healthcare
EPS für Sinopharm Group Co. Ltd. (1099)
EPS zum June 2026 TTM: $0.33
Laut den aktuellen Finanzberichten und dem Aktienkurs von Sinopharm Group Co. Ltd. beträgt das aktuelle EPS des Unternehmens (TTM) $0.33. Am Ende des Jahres 2023 betrug das EPS $0.41 eine Steigerung gegenüber dem EPS von 2022, das $0.40 betrug.
EPS-Verlauf von Sinopharm Group Co. Ltd. von 2006 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $0.33 | 5.19% |
| 2024 | $0.31 | -24.43% |
| 2023 | $0.41 | 3.51% |
| 2022 | $0.40 | 1.02% |
| 2021 | $0.39 | 10.80% |
| 2020 | $0.35 | -31.22% |
| 2019 | $0.51 | 11.57% |
| 2018 | $0.46 | 13.14% |
| 2017 | $0.41 | 68.31% |
| 2016 | $0.24 | 15.57% |
| 2015 | $0.21 | 16.85% |
| 2014 | $0.18 | 22.15% |
| 2013 | $0.15 | 11.56% |
| 2012 | $0.13 | 25.60% |
| 2011 | $0.10 | 30.39% |
| 2010 | $0.08 | 3.48% |
| 2009 | $0.08 | 46.97% |
| 2008 | $0.05 | 67.62% |
| 2007 | $0.03 | 309.09% |
| 2006 | $0.01 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $37.53 | 11,408.74% |
US
|
|
| - | - |
US
|
|
| $7.27 | 2,129.38% |
US
|
|
| - | - |
US
|
|
| $0.04 | -86.69% |
AU
|
